Immuron is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a class of polyclonal antibodies. Co.'s oral polyclonal antibodies provide delivery within the gastrointestinal track but do not cross into the bloodstream. Co. markets its commercial products Travelan® and Protectyn® in Australia, both products are listed medicines on the Australian Register for Therapeutic Goods. Co. also markets Travelan® in Canada where it is licensed as a natural health product indicated to reduce the risk of travelers' diarrhea, and market Travelan® as a dietary supplement for digestive tract protection. The IMRN stock yearly return is shown above.
The yearly return on the IMRN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the IMRN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|